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Abstract
Objectives—We examined the association between anticholinergic medication exposure and 
subsequent cognitive and physical function in patients with delirium superimposed on dementia 
during rehabilitation. We also examined length of stay and discharge disposition by 
anticholinergic medication exposure.
Design—In this secondary analysis we used control group data from an ongoing randomized 
clinical trial.
Setting/Participants—Participants with delirium and dementia were enrolled at admission to 
post-acute care. These 99 participants had a mean age of 86.11 (± 6.83) years; 67.6% were female; 
98% were Caucasian; and 33% were positive for at least one APOE e4 allele.
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Measures—We obtained daily measures of cognitive and physical function using: Digit Span; 
memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; 
Confusion Assessment Method; and Barthel Index. Anticholinergic medication exposure was 
measured weekly using the Anticholinergic Cognitive Burden Scale.
Results—Using multilevel models for time we found that greater use of clinically relevant 
anticholinergic medications in the previous week reduced cognitive and physical function, as 
measured by Digit Span Backwards and the Barthel Index, in the current week. There was no 
effect of anticholinergic medication use on delirium severity, and APOE status did not moderate 
any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer 
length of stay but not discharge disposition.
Conclusion—For vulnerable older adults, anticholinergic exposure represents a potentially 
modifiable risk factor for poor attention, working memory, physical function and greater length of 
stay during rehabilitation.
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Objective
Medications with anticholinergic effects are prescribed for many clinical problems common 
to older adults. It is estimated that between 20 and 50% of older adults take at least one 
medication with anticholinergic effects to manage a variety of medical and psychiatric 
symptoms such as urine incontinence, depression, or insomnia [1]. In addition to their 
beneficial effects these medications have clinically relevant adverse effects that impact the 
central nervous system [1]. A recent systematic review of 46 studies evaluated these effects 
in 60,944 participants and found strong evidence for an association between increased 
anticholinergic exposure and deteriorating cognition, and consistent evidence for an 
association with a decline in physical function [2]. The association with delirium and 
mortality was inconclusive. Despite appreciable risks, the proportion of older adults 
prescribed anticholinergic medications has actually increased between 1995 and 2010 [3].
Older adults with dementia have lower cholinergic activity than those with normal cognition 
making them potentially more sensitive to anticholinergic medications [4]. They are also 
more likely to be carriers of the APOE e 4 allele than the general population. In some 
studies [5] but not others [6] APOE e 4 allele carriers were found to have a greater 
sensitivity to anticholinergic medications.
The adverse effects of anticholinergic medications on community-dwelling [7, 8], 
hospitalized [9], and institutionalized [10, 4] older adults with dementia have been 
described. We did not find any studies that examined the effects of anticholinergic 
medication exposure on cognitive and physical function in older adults with dementia in 
post-acute care settings. This was surprising given the growing number of people with 
dementia who require rehabilitation following hospitalization and the strong emphasis on 
functional outcomes in these settings. Data indicate that patients with dementia benefit from 
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post-acute care and can experience significant functional improvements over their admission 
status. [11]
Patients with dementia who receive rehabilitation following an acute medical event have 
complex medical and psychiatric comorbidity that may interfere with their recovery such as 
urine incontinence, depression, insomnia, pain and gastrointestinal symptoms. The 
management of this comorbidity may include prescribing medications with anticholinergic 
activities such as oxybutynin for urine incontinence, paroxetine for major depression, or 
diphenhydramine for insomnia. In the case of depression, the use of antidepressants may be 
life saving. In the case of delirium, however, the evidence for use of antipsychotic 
medications outside of intensive care settings is weak. [12]
The purpose of this study was to examine the association between anticholinergic 
medication exposure and subsequent cognitive (attention, memory, orientation, executive 
function and delirium) and physical function in patients with delirium superimposed on 
dementia who receive rehabilitation in post-acute care settings. We explore the moderating 
effect of APOE status on the association of anticholinergic medication exposure to 
functional outcomes because the evidence is not consistent in the literature. Delirium 
superimposed on dementia is common on admission to post-acute care settings and may 
compromise rehabilitation goals [12]. Thus we examine length of stay and discharge 
disposition by anticholinergic medication exposure.
Methods
Data from an ongoing randomized clinical trial were used to address the aim of the study 
(ClinicalTrials.gov identifier: NCTO1267682). The efficacy of cognitively stimulating 
activities for resolving delirium in patients with dementia during rehabilitation is being 
tested in that trial. The protocol received Institutional Review Board approval and was 
published [13].
Setting and Sample
Participants were recruited and enrolled at the time of admission to one of eight skilled 
nursing facilities located in central and northeast Pennsylvania that provide post-acute care. 
All admissions to the facility followed an inpatient hospitalization.
Eligible participants were those 65 years of age or older, community-dwelling prior to 
hospitalization, having a knowledgeable informant and both dementia and delirium on 
admission to the post-acute care facility. The diagnosis of dementia was based on a 
Modified Blessed Dementia Rating Scale [14] score of three or greater and a Clinical 
Dementia Rating [15] score ranging from 0.5 to 2.0, indicating mild to moderate stage 
dementia. The presence of delirium was established by screening potential participants using 
two instruments: 1) the Mini-Mental State Exam [16], a 30-item cognitive screen, and 2) the 
Confusion Assessment Method [17], a standardized diagnostic algorithm for delirium. All 
dementia and delirium diagnoses were adjudicated by a panel of three experts in dementia: a 
neuropsychologist, a neurologist, and a geriatrician. Exclusion criteria included having: any 
neurological or neurosurgical disease associated with cognitive impairment other than 
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dementia, including Parkinson’s disease with Lewy bodies, Huntington’s disease, normal 
pressure hydrocephalus, seizure disorder, subdural hematoma, head trauma, or known 
structural brain abnormalities; a life expectancy of less than six months; acute major 
depression or psychosis; severe hearing and vision impairment; and being nonverbal.
Following written consent, participants were randomly assigned to one of two conditions: 
cognitive stimulation (intervention) or usual care (control). For this study only participants 
assigned to usual care were included.
Procedure
Participants were assessed by trained and blinded research staff using the instruments 
described below. Demographic variables and APOE genotype were obtained at baseline. 
Observational measures of cognition (attention, memory, orientation, executive function and 
delirium) and physical function were taken daily for 30 days or until discharge. A weekly 
medical chart audit was conducted during which data on medications with anticholinergic 
effects and their administration over the past week were extracted. Three months following 
admission to the facility a phone interview was conducted with the participant's responsible 
party to determine discharge disposition (community, nursing home, death).
Measures
Anticholinergic medication exposure was defined as used vs. not used, and was measured 
weekly using the Anticholinergic Cognitive Burden (ACB) Scale [18, 1]. The ACB is an 
expert based practical index that ranks the severity of a medication’s anticholinergic activity 
on cognition using a scale of: 1 (mild, with no known clinically relevant cognitive effects); 2 
(moderate) or 3 (severe), both with clinically relevant effects.
APOE genotype was determined by extracting DNA from buccal swabs using a protocol 
optimized by the Institute of Psychiatry in London [19]. To identify the six APOE genotypes 
comprising the APOE e2, e3 and e4 alleles, two single nucleotide polymorphisms (SNPs) 
were assayed using the TaqMan Allele Discrimination method.
Physical function was measured using the Barthel Index [20], a commonly used ordinal 
scale for assessing activities of daily living in patients receiving inpatient rehabilitation. The 
Index has ten items (seven for self-care and three for mobility) that are scored in steps of 
five points with a total score range of 0 (totally dependent) to 100 (fully independent). The 
Barthel Index is a reliable indicator of functional ability in older adults when administered 
by face-to-face interview (ICC 0.89) and on testing by different observers (ICC 0.95–0.97).
Attention was measured using Digit Span Forward and Digit Span Backward [21]. 
Participants are given increasingly longer sequences of digits to repeat initially forwards 
then backwards and receive a point for each correct sequence. The assessment ends when 
the participant misses two sequences in a row. The maximum possible score is 16 (forward) 
and 14 (backward). Higher scores indicate better attention and working memory. Median 
reliabilities reach .97 and .96 for forward and backward spans respectively.
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Memory and orientation were measured using the memory and orientation items from the 
Montreal Cognitive Assessment, a valid assessment of cognition that shows good agreement 
with existing screening tools and global measures (convergent validity) [22].
Executive function was measured using the CLOX [23]. This instrument has two parts: 
CLOX 1, a free drawing of a specified time, and CLOX 2, a simple copying task. Both steps 
are rated on 14 items with scores ranging from 0 to 15, higher scores indicate better 
executive function. The CLOX has an internal consistency of .82, interrater reliability of .94 
(CLOX 1) and .93 (CLOX 2) and correlates strongly with other measures of cognitive 
function in healthy and cognitively impaired older adults.
Delirium severity was measured using two instruments: 1) Montreal Cognitive Assessment 
and 2) the Confusion Assessment Method. The severity score was calculated using a method 
developed by Inouye and colleagues [24]. Using both instruments, the responses to the 
following items were summed: Confusion Assessment Method fluctuating course item (0–
1); Montreal Cognitive Assessment attention item (0–5); and Confusion Assessment Method 
level of consciousness item (0–2). Total scores can range from one to eight with higher 
scores indicating greater delirium severity.
Analytic strategy
Data in the current study were treated as nested with three levels of nesting: days nested in 
weeks, weeks nested in persons. Multilevel models (SAS proc mixed) allowed individuals to 
have different intercepts at baseline and at the beginning of each week to account for 
learning and recovery over the course of the study. Using the chi-square likelihood ratio test, 
initial models testing whether including nesting by facility improved model fit indicated that 
there was not sufficient variability at this level. At level 1 (day), day in study was included 
to control for changes due to treatment. Anticholinergic medication usage, the primary 
predictor, was included at level 2 (week) as well as previous week’s cognitive and physical 
function performance and the number of days in the facility that week. The latter was 
included because some individuals were discharged earlier in the week compared with 
others. This variable allowed us to control for differences in the number of days in the 
facility across weeks. We were interested in anticholinergic medications with a clinically 
relevant effect. Therefore weekly moderate and severe anticholinergic medication use was 
summarized as a binary variable: weeks with any moderate or severe anticholinergic 
medication administration(ACB score of 2 or 3) were coded as 1; and weeks without any 
moderate or severe anticholinergic medication administration (ACB score of 1) were coded 
as 0. This was also supported by the data; most individuals received just one type of 
moderate or severe anticholinergic medication each week. Because medication 
administration was collected at weekly intervals, we chose the prior week exposure rather 
than the current week as exposure to some medications may occur on an as-needed basis and 
could have occurred after outcome measures were performed. For significant effects, 
pseudo-R2 was calculated as a measure of the variance accounted for in the outcome 
variable by anticholinergic use [25].
At level three, age, gender, education level, ethnicity, clinical dementia rating score, APOE 
status, and comorbidity scores were entered as person-level covariates. Models included a 
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cross-level interaction between APOE status and anticholinergic medication usage to test for 
moderation of the usage effect.
Results
The sample had a mean age of 86.11 (± 6.83) years, a Charlson Co-morbidity Index score 
[26] of 2.97 (± 1.96), and a Clinical Dementia Rating score of 1.20 (± 0.59); 67.6% were 
female; 98% were Caucasian; and 33% were positive for at least one APOE e4 allele. These 
99 participants provided 474 weeks of data for analysis.
Eighty one participants (81.8%) were taking a medication with mild anticholinergic effects 
and 25 (25.2%) were taking one with a moderate or severe effect. Only 15 participants 
(15.1%) received no medication with anticholinergic properties throughout the study. 
Medications with mild anticholinergic effects were administered on 78.3% of weeks (nweeks 
= 371). Medications with moderate or severe anticholinergic effects were administered on 
22.2% of weeks (nweeks = 105). More than one medication with moderate or severe 
anticholinergic effects was administered on only 7.6% of weeks (nweeks = 8). Those 
individuals who were given medications with moderate or severe anticholinergic effects 
received those drugs consistently across weeks (i.e. 77% of weeks). Quetiapine, 
Dicycloverine, Carbamazepine, Paroxetine and Amitriptyline were the most frequently 
administered level 2/3 anticholinergic medications. Table 1 lists the anticholinergic 
medications administered by frequency and severity of anticholinergic activity.
Descriptive statistics for the outcome measures appear in Table 2. Tables 3 and 4 include the 
estimates for the models predicting the outcomes of interest. As expected, previous week’s 
performance on the cognitive tasks (attention, memory, orientation, and executive function) 
was significantly related to current performance with higher previous performance 
predicting higher current performance. Greater dementia severity predicted lower 
performance on all of the cognitive measures. Previous week use of a medication with 
moderate or severe anticholinergic effects predicted poorer performance on the Digit Span 
Backwards task (b = −.575, SE = .259, df = 948, t = −2.22, p = .03, pseudo-R2 = .129). None 
of the other effects for anticholinergic medication use were significant. There was no 
evidence of moderation by APOE status.
Delirium severity was significantly and positively associated across weeks. Higher dementia 
severity scores were related to greater delirium severity scores. Younger age, lower 
comorbidities, and presence of the APOE 4 allele were related to higher delirium severity 
scores. Use of a medication with moderate or severe anticholinergic effects was not related 
to delirium severity.
Similar to the cognitive performance measures, physical function scores from the previous 
week were positively related to current scores. Older individuals had lower physical function 
scores compared to younger individuals. Individuals with higher comorbidity scores also 
had higher physical function scores compared to those with lower comorbidity scores. Use 
of a medication with moderate or severe anticholinergic effects in the previous week 
predicted a lower physical function score in the next week (b = −5.761, SE = 1.994, df = 
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1081, t=−2.89, p = .004, pseudo-R2 = .052). APOE status did not moderate the effect of 
anticholinergic medication use on physical function scores.
Supplemental analysis
To determine whether use of anticholinergic medications increased length of stay, nonlinear 
models (SAS proc genmod using a negative binomial distribution and log link) examined 
number of days in facility predicted by anticholinergic medication use and the level 3 
covariates from previous models. Results of these models also appear in Tables 3 and 4. Use 
of a moderate or severe anticholinergic medication increased the number of days spent in a 
rehabilitation facility (Mno ACB = 16.77 days vs. MACB = 21.04 days). We found no 
difference in discharge disposition (community, nursing home, or death) by anticholinergic 
medication use.
Conclusions
This is one of the first studies to examine the effects of anticholinergic medication exposure 
on rehabilitation outcomes in patients with delirium superimposed on dementia, a group at 
high risk for poor outcomes following hospitalization. We controlled for socio-demographic 
and health related factors (age, gender, education, ethnicity, comorbidity, dementia severity) 
allowing us to see the independent effect of anticholinergic medications on cognition, 
physical function, and length of stay. We found an independent and significant negative 
effect of clinically relevant anticholinergic medication use in the previous week on 
performance in two areas: Digit Span Backwards, a measure of attention and working 
memory, and the Barthel Index, a measure of physical function. There was no effect of 
anticholinergic medication use on delirium severity, and APOE status did not moderate any 
outcomes. We also found an association between use of these medications and longer length 
of stay but not discharge disposition.
The cognitive outcomes we measured included several domain-specific cognitive functions 
as opposed to a single measure of global cognition such as the MMSE, the outcome most 
often reported in prior research [2]. Our measurement approach likely improved specificity, 
and our findings point to the possibility that anticholinergic medications may not affect all 
cognitive domains equally. There are several other possible reasons for our cognitive 
findings. First, all participants were recovering from an acute illness and for the vast 
majority their delirium was resolving. The lack of effect on most cognitive domains may 
have been due to this general improvement in neurocognition. Second, the cognitive effects 
of anticholinergic medications might be difficult to detect in people with dementia as we 
found in an earlier study [10] and as reported by Fox and colleagues [27]. Nonetheless, we 
did see an effect of these medications on Digit Span Backwards, a measure of attention and 
working memory [28]. These cognitive functions are critical for performance of everyday 
tasks [29], and their impairment has been associated with reduced ability to carry out 
activities of daily living [30]. Our finding is important when considered in light of the 
results we report on physical function, and could adversely impact transitions from post-
acute care to home, as we found and as discussed below.
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In addition to their cognitive effects, recent evidence indicates that medications with 
anticholinergic effects impact "global parameters" such as physical function in older adults 
[31]. Our findings are similar, and extend those of Koshoedo and colleagues who found a 
negative effect of these medications on physical function in older adults who undergo 
orthopedic rehabilitation [32]. In that study less than 2% of the sample had a history of 
dementia while in this study all participants had an adjudicated diagnosis of dementia. 
Worsening functional status during rehabilitation is an important risk factor for 30-day 
unplanned re-hospitalizations [33], the rate of which is over 23% in post-acute care facilities 
[34]. For people with dementia, the loss of physical function is a major risk factor for 
permanent institutionalization, and contributes heavily to the national burden of healthcare 
costs [35].
Medicare expenditures for post-acute care are second only to inpatient hospital care, and 
length of stay drives much of this cost. A recent Office of the Inspector General (OIG) 
report indicated that outcomes in post-acute care settings are often suboptimal and costly 
due to poor-quality treatment.[36] Problems with medication management were among the 
most prevalent reasons for the incurrence of harms that involved re-hospitalization or 
prolonged the length of stay. Our findings indicate that patients who received anticholinergic 
medications with significant clinical effects had a length of stay that was on average 4 days 
longer than patients not receiving these medications. These findings are similar to those of 
Lowery and colleagues [31] who also found a negative impact of anticholinergic 
medications on hospital length of stay in their unadjusted analyses.
The results of this study have important clinical implications for maximizing functional 
potential and reducing the costs of care for a growing number of people with dementia in 
need of rehabilitation. Many co-morbid conditions have alternative therapeutic options with 
less negative impact on recovery. The detrimental effects of anticholinergic medications 
during post-acute care might be addressed by stopping unnecessary medications,[37] 
switching to an alternative medication with a lower anticholinergic effect or using non-
pharmacological interventions to address clinical problems that respond to them.[38] For 
example: in place of using antipsychotic medications, reversible contributions to delirium 
such as infection should be identified and appropriately treated[12]; in place of using 
diphenhydramine, sleep hygiene behaviors or a trial of melatonin can be attempted to reduce 
sleep problems[39]; and in place of using oxybutynin, a non-anticholinergic medication or 
prompted voiding might be instituted to address incontinence.[40] Although general de-
prescribing trials have shown improvements in quality of life without significant adverse 
withdrawal effects,[41] de-prescribing studies of anticholinergics have shown 
anticholinergic reduction is possible but little is known about the effects on clinical 
outcomes, particularly among older adults with dementia.[42]
Our findings and that of others also have implications across settings of care. Many 
medications with strong anticholinergic activity, such as diphenhydramine, are readily 
available over the counter and consumed by older adults in the community as an over the 
counter sleep aide. It is not known if anticholinergic-induced cognitive impairment is 
reversible, but recent evidence suggests that higher cumulative use of anticholinergic 
medications is associated with an increased risk for dementia [43]. The potential for these 
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medications to impair cognition and function is an important public health message and a 
needed targeted area for education of both consumers and healthcare professionals.
We acknowledge several limitations of this study. Our observational study used data from 
an ongoing clinical trial; unmeasured confounding variables could have biased our 
estimates. We did, however, control for a number of socio-demographic and health related 
factors that have shown an association to our outcomes. Our sample size was not large and 
we conducted several tests relative to our outcomes increasing the potential for obtaining 
statistical significance by chance. We did, however, make use of multiple observations over 
time in our within person analyses. These within-person analyses improve the precision of 
measurement so that even small effects could potentially be detected; and we acknowledge 
that some of our effects were small.
We did not have data to establish the duration of anticholinergic medication use prior to 
post-acute care admission. We did, however, find that the vast majority of participants who 
received strong anticholinergic medications did so consistently across the study duration. 
We also did not have data on the dosage of medications administered. Lack of data on 
duration and dosage may have underestimated the true effect of strong anticholinergics in 
our analyses, as seen in recent work by Gray and colleagues [43].
There are also several strengths of the study. The sample was composed of individuals with 
delirium superimposed on dementia who were receiving rehabilitation, a growing population 
that has not been systematically studied to any extent. We used data on actual medication 
administration, not just prescription order data. Rather than using global measures of 
cognition to assess anticholinergic effects, we used measures of specific cognitive domains. 
Lastly, our study data were taken from an ongoing clinical trial that used reliable and valid 
measures.
The goal of post-acute care is to optimize function. For people with dementia, appropriate 
anticholinergic medication management may help achieve rehabilitation goals and reduce 
the cost of care.
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Table 1
Most commonly used anticholinergic medications
Mild Anticholinergic
Medications
Moderate/Severe Anticholinergic
Medications
Drug
Number of
administrations Drug
Number of
administrations
Metoprolol 3403 Quetiapine 584
Furosemide 1312 Dicycloverine 161
Warfarin 918 Carbamazepine 126
Hydralazine 729 Paroxetine 124
Risperidone 624 Amitriptyline 124
Isosorbide 579 Methocarbamol 119
Alprazolam 418 Olanzapine 63
Digoxin 362 Diphenhydramine 49
Atenolol 348 Hydroxyzine 43
Prednisone 301 Meclizine 38
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Table 2
Descriptive statistics for outcome measures
Outcome Mean SD Min Max
Clox 1 3.989 3.597 0 14
Barthel 39.323 25.232 0 100
Orientation 3.097 1.945 0 7
Digits forward 8.022 2.897 0 15
Digits backward 2.719 2.205 0 10
Memory 0.352 0.736 0 3
Delirium severity 0.955 1.546 0 7
Length of stay† 21.758 8.442 0 30
Note.
†Calculated as the total number of days in the study. All other values represent performance at baseline.
Am J Geriatr Psychiatry. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kolanowski et al. Page 15
Ta
bl
e 
3
R
es
ul
ts 
of
 m
ul
til
ev
el
 m
od
el
s u
sin
g 
w
ee
kl
y 
m
ild
 a
nt
ic
ho
lin
er
gi
c 
m
ed
ic
at
io
n 
us
e 
to
 p
re
di
ct
 o
ut
co
m
es
C
lo
x 
1
Ba
rt
he
l
O
ri
en
ta
tio
n
D
ig
it 
fo
rw
ar
d
D
ig
it 
Ba
ck
w
ar
d
M
em
or
y
Le
ng
th
 o
f s
ta
y
Pr
ed
ic
to
r
b
SE
b
SE
b
SE
b
SE
b
SE
b
SE
b
SE
A
ny
 m
ild
 A
C
0.
02
4
0.
53
6
−
3.
41
1
2.
14
5
−
0.
17
8
0.
21
3
0.
32
7
0.
47
3
−
0.
40
6
0.
28
7
−
0.
21
2
0.
16
1
0.
10
5
0.
12
4
G
en
de
r
−
1.
68
9
0.
93
6
0.
81
6
4.
93
9
−
0.
04
3
0.
46
8
0.
13
2
0.
74
8
−
0.
09
6
0.
54
8
−
0.
35
3
0.
24
8
0.
10
3
0.
10
3
Et
hn
ic
ity
−
1.
75
5
2.
76
7
29
.5
90
15
.2
68
1.
47
1
1.
43
3
1.
28
6
2.
23
9
−
0.
79
5
1.
61
6
1.
25
3
0.
73
5
0.
16
6
0.
33
9
Ch
ar
lso
n
0.
12
2
0.
21
1
2.
43
3
1.
14
6
0.
06
0
0.
10
8
0.
00
7
0.
16
8
0.
02
0
0.
12
2
0.
00
9
0.
05
5
0.
01
6
0.
02
4
CD
R
−
3.
12
6
0.
74
8
−
4.
25
5
3.
78
1
−
1.
26
0
0.
36
3
−
1.
25
1
0.
57
3
−
1.
33
0
0.
41
9
−
0.
65
3
0.
19
0
0.
03
1
0.
08
2
A
ge
−
0.
02
8
0.
07
6
−
0.
96
0
0.
36
0
−
0.
03
0
0.
03
5
0.
13
3
0.
05
9
0.
06
5
0.
04
5
−
0.
04
0
0.
02
0
0.
01
2
0.
00
8
A
PO
E
−
1.
16
5
1.
34
0
−
3.
41
0
6.
12
1
−
0.
12
4
0.
59
2
−
1.
60
6
1.
11
1
−
1.
31
4
0.
73
4
0.
16
4
0.
37
2
0.
06
5
0.
10
8
A
PO
E*
m
ild
 A
C
1.
69
8
1.
07
7
5.
71
0
4.
28
3
0.
19
2
0.
42
5
0.
16
5
0.
94
9
0.
88
5
0.
57
4
0.
12
6
0.
32
1
-
-
-
-
R
ep
et
iti
on
0.
00
2
0.
01
0
0.
10
9
0.
03
5
0.
00
6
0.
00
4
0.
00
4
0.
00
8
0.
00
9
0.
00
5
0.
00
8
0.
00
3
-
-
-
-
Ed
uc
at
io
n
1.
50
8
1.
54
8
21
.8
40
8.
35
8
0.
82
1
0.
78
6
−
1.
50
8
1.
22
9
−
0.
82
9
0.
88
8
0.
39
5
0.
40
3
0.
00
3
0.
18
2
Pr
ev
io
us
 w
ee
k's
 p
er
fo
rm
an
ce
0.
35
6
0.
08
1
0.
30
4
0.
06
3
0.
12
2
0.
05
8
0.
27
5
0.
06
2
0.
14
8
0.
06
4
0.
41
9
0.
06
1
-
-
-
-
D
ay
s W
P
−
0.
19
3
0.
16
2
−
0.
18
5
0.
53
6
0.
04
1
0.
06
0
−
0.
09
2
0.
13
0
0.
01
6
0.
07
8
0.
02
7
0.
04
4
-
-
-
-
N
ot
e.
 A
C 
= 
an
tic
ho
lin
er
gi
c;
 B
ol
d 
va
lu
es
 p
 <
 .0
5;
 b
 =
 u
ns
ta
nd
ar
di
ze
d 
re
gr
es
sio
n 
w
ei
gh
t; 
t-t
es
t (
df b
et
w
ee
n 
=
 9
0,
 d
f w
ith
in
 
=
 1
09
9)
Am J Geriatr Psychiatry. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kolanowski et al. Page 16
Ta
bl
e 
4
R
es
ul
ts 
of
 m
ul
til
ev
el
 m
od
el
s u
sin
g 
w
ee
kl
y 
m
od
er
at
e/
se
ve
re
 a
nt
ic
ho
lin
er
gi
c 
m
ed
ic
at
io
n 
us
e 
to
 p
re
di
ct
 o
ut
co
m
es
C
lo
x 
1
Ba
rt
he
l
O
ri
en
ta
tio
n
D
ig
it 
Fo
rw
ar
d
D
ig
it 
Ba
ck
w
ar
d
M
em
or
y
D
el
ir
iu
m
se
v
er
ity
Le
ng
th
 o
f s
ta
y
Pr
ed
ic
to
r
b
SE
b
SE
b
SE
b
SE
b
SE
b
SE
b
SE
b
SE
A
ny
 A
C
0.
50
2
0.
50
8
−
5.
76
1
1.
99
4
−
0.
19
5
0.
20
3
0.
23
5
0.
42
6
−
0.
57
5
0.
25
9
−
0.
00
8
0.
14
4
0.
16
0
0.
17
0
0.
22
7
0.
10
9
G
en
de
r (
ref
 = 
fem
ale
)
−
1.
85
3
0.
96
1
2.
03
7
4.
98
3
−
0.
00
6
0.
46
3
0.
09
2
0.
75
3
0.
00
1
0.
54
8
−
0.
36
0
0.
24
7
−
0.
27
4
0.
13
4
−
0.
13
9
0.
10
2
Et
hn
ic
ity
 (r
ef 
= C
au
ca
sia
n)
−
1.
77
1
2.
83
5
31
.5
54
15
.4
04
1.
47
9
1.
41
8
1.
38
5
2.
25
1
−
0.
65
6
1.
61
3
1.
14
9
0.
73
3
−
0.
58
6
0.
45
1
−
0.
27
7
0.
33
7
Ch
ar
lso
n
0.
12
2
0.
21
5
2.
33
4
1.
15
2
0.
05
3
0.
10
6
0.
01
9
0.
16
8
−
0.
00
1
0.
12
1
0.
00
1
0.
05
5
−
0.
07
0
0.
03
1
0.
02
0
0.
02
4
CD
R
−
3.
08
6
0.
75
5
−
3.
65
5
3.
79
8
−
1.
22
5
0.
35
7
−
1.
30
9
0.
56
7
−
1.
20
7
0.
41
4
−
0.
61
7
0.
18
7
0.
60
0
0.
10
8
0.
02
1
0.
07
9
A
ge
−
0.
03
6
0.
07
7
−
1.
05
1
0.
36
3
−
0.
03
5
0.
03
4
0.
13
6
0.
05
9
0.
05
0
0.
04
5
−
0.
04
1
0.
02
0
−
0.
02
5
0.
01
1
0.
01
6
0.
00
8
A
PO
E 
(re
f =
 pr
ese
nt)
0.
27
0
1.
01
8
1.
19
4
5.
04
3
−
0.
00
3
0.
47
2
−
1.
38
9
0.
76
1
−
0.
65
6
0.
54
5
0.
23
3
0.
24
8
−
0.
32
2
0.
33
2
0.
09
0
0.
10
5
A
PO
E*
A
C
−
0.
23
8
0.
99
8
2.
23
5
3.
94
2
0.
29
8
0.
40
0
−
0.
64
3
0.
83
6
0.
76
2
0.
50
7
0.
33
3
0.
28
2
−
0.
05
0
0.
34
5
-
-
-
-
R
ep
et
iti
on
−
0.
00
1
0.
01
0
0.
11
3
0.
03
5
0.
00
6
0.
00
4
0.
00
4
0.
00
8
0.
00
9
0.
00
5
0.
00
7
0.
00
3
0.
00
0
0.
00
6
-
-
-
-
Ed
uc
at
io
n
1.
70
6
1.
57
1
22
.4
38
8.
40
5
0.
84
2
0.
77
3
−
1.
49
3
1.
22
5
−
0.
72
8
0.
88
0
0.
39
1
0.
39
8
−
0.
01
3
0.
23
1
−
0.
00
1
0.
17
6
Pr
ev
io
us
 w
ee
k's
 p
er
fo
rm
an
ce
0.
35
3
0.
08
0
0.
31
8
0.
06
3
0.
12
3
0.
05
8
0.
27
0
0.
06
2
0.
16
8
0.
06
4
0.
42
7
0.
06
1
1.
15
5
0.
07
9
-
-
-
-
D
ay
s W
P
−
0.
22
0
0.
16
1
−
0.
12
1
0.
53
0
0.
04
5
0.
06
0
−
0.
10
2
0.
13
0
0.
02
6
0.
07
8
0.
02
7
0.
04
4
0.
29
9
0.
08
9
-
-
-
-
N
ot
e.
 A
C 
= 
an
tic
ho
lin
er
gi
c;
 B
ol
d 
va
lu
es
 p
 <
 .0
5;
 b
 =
 u
ns
ta
nd
ar
di
ze
d 
re
gr
es
sio
n 
w
ei
gh
t; 
t-t
es
t (
df b
et
w
ee
n 
=
 9
0,
 d
f w
ith
in
 
=
 1
09
9)
Am J Geriatr Psychiatry. Author manuscript; available in PMC 2016 December 01.
